EUS-guided Response Assessment to NSBB
Study Details
Design, interventions, and primary outcomes
About This Study
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.
Design
Interventions / Regimen
- Procedure: endoscopic ultrasound-guided portal pressure measurement — The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
Primary Outcomes
- EUS-guided response assessment to NSBB in the treatment of CSPH. (Three months)
Phase: NA
Status: Recruiting
Start Date: 2024-07-17
Completion: 2026-12
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
- Schalk van der Merwe, MD, PhD (PRINCIPAL_INVESTIGATOR) - Universitaire Ziekenhuizen KU Leuven
- Procedure: endoscopic ultrasound-guided portal pressure measurement — The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.